Northern Oak Wealth Management Inc. trimmed its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 1.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 132,066 shares of the biopharmaceutical company’s stock after selling 1,878 shares during the quarter. Bristol-Myers Squibb comprises approximately 1.4% of Northern Oak Wealth Management Inc.’s portfolio, making the stock its 21st biggest position. Northern Oak Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $7,182,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Welch Investments LLC boosted its holdings in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 79 shares during the period. Crestwood Advisors Group LLC acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at approximately $116,000. Blue Chip Partners Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 60 shares during the period. Finally, Heritage Trust Co acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at approximately $123,000. 68.80% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/13/bristol-myers-squibb-company-bmy-shares-sold-by-northern-oak-wealth-management-inc.html.

Several equities research analysts have recently weighed in on BMY shares. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective for the company in a report on Monday, June 5th. BMO Capital Markets reissued a “sell” rating and issued a $49.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Jefferies Group LLC restated a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, June 5th. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Deutsche Bank AG set a $55.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $62.54.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.

Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.65% during mid-day trading on Wednesday, hitting $62.61. The company had a trading volume of 1,507,421 shares. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47. The company has a market cap of $102.68 billion, a PE ratio of 22.87 and a beta of 1.18. The company’s 50 day moving average price is $57.73 and its 200-day moving average price is $55.76.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. Bristol-Myers Squibb’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.69 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.